Mercury Laboratories declares ₹3.5 per share final dividend for FY26
Mercury Laboratories declared a ₹3.5 per share final dividend for FY26, subject to AGM approval. With a record date of September 21, 2026, the company emphasized strict adherence to TDS norms under the Income Tax Act, 2025. Residents face a 10% TDS unless exempt, while non-residents must provide DTAA documents to claim treaty benefits. Electronic payment mandates require immediate KYC updates.

*this image is generated using AI for illustrative purposes only.
Mercury Laboratories has declared a final dividend of ₹3.5 per equity share for the financial year ended March 31, 2026 (FY26). The Board of Directors recommended this payout during its meeting held on May 29, 2026, pending approval from shareholders at the ensuing Annual General Meeting (AGM).
The company has designated Monday, September 21, 2026 as the record date to determine eligibility for the dividend. In line with regulatory mandates requiring electronic dividend payments, shareholders must ensure their bank account details, including IFSC codes, are updated with their Depository Participants or the Registrar and Share Transfer Agent.
Tax Deduction at Source (TDS) Implications
Under the prevailing provisions of the Income Tax Act, 2025, Mercury Laboratories will deduct tax at source on dividend payouts. The applicable TDS rates vary based on the shareholder's residential status and submitted documentation:
| Shareholder Category: | Applicable TDS Rate: | Key Requirements |
|---|---|---|
| Resident Individuals | 10% | Exempt if aggregate dividend ≤ ₹10,000; Form 121 required for nil deduction |
| Resident Entities (MFs/AIFs) | Nil | Documentary evidence of exemption status under Schedule VII |
| Non-Residents (FII/FPI) | 20% + surcharge/cess | DTAA benefits available via Form 41 and Tax Residency Certificate |
Resident individual shareholders can avoid TDS if their total dividend income from the company does not exceed ₹10,000 in the tax year 2026-2027. Those eligible for lower or nil rates must submit a self-attested certificate under Section 395 of the Act. Failure to link Aadhaar with PAN may result in TDS at a higher rate of 20%.
Compliance and Documentation
Non-resident shareholders seeking benefits under Double Taxation Avoidance Agreements (DTAA) must submit specific documents by the record date. These include a self-attested PAN, Tax Residency Certificate (TRC), and e-filed Form 41. The company reserves the right to apply standard TDS rates if documentation is incomplete or unsatisfactory.
Shareholders holding shares in physical mode must submit service requests along with cancelled cheques and PAN copies to the Registrar. Demat holders must update details directly with their Depository Participants. No claims against the company will be entertained for taxes deducted due to missing or inaccurate information.
Historical Stock Returns for Mercury Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.27% | +0.58% | -11.33% | -6.63% | -9.00% | +10.59% |
How might Mercury Laboratories' dividend payout ratio for FY26 compare to its historical averages and peer companies in the pharmaceutical sector?
What impact could the mandatory TDS deductions have on the net yield for non-resident investors relying on DTAA benefits, given the strict documentation deadlines?
Will the Board of Directors propose any additional capital allocation strategies, such as share buybacks or reinvestment in R&D, alongside this dividend declaration?


































